PCVX Latest Press Releases

-- October 9, 2026 --

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares and Convertible Senior Notes Globe Newswire 4:05 PM

-- October 6, 2026 --

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes Globe Newswire 10:48 PM

-- October 5, 2026 --

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes Globe Newswire 4:28 PM

Biotech Brainiacs and Breakthroughs Globe Newswire 9:51 AM

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate Globe Newswire 6:00 AM

-- October 4, 2026 --

Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company's 31-Valent Pneumococcal Conjugate Vaccine Candidate Globe Newswire 5:00 PM

-- September 3, 2026 --

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data Globe Newswire 4:05 PM

-- August 27, 2026 --

Vaxcyte to Participate in Upcoming Investor Conferences Globe Newswire 4:05 PM

-- August 5, 2026 --

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- July 8, 2026 --

Vaxcyte to Participate in Upcoming Investor Conferences Globe Newswire 4:05 PM

Market Data Delayed 15 Minutes